rhamnazin: has both antiangiogenic and antineoplastic activities
ID Source | ID |
---|---|
PubMed CID | 5320945 |
CHEMBL ID | 457148 |
CHEBI ID | 133721 |
SCHEMBL ID | 39443 |
MeSH ID | M000605781 |
Synonym |
---|
3,5,4'-trihydroxy-7,3'-dimethoxyflavone |
3,5-dihydroxy-2-(4-hydroxy-3-methoxy-phenyl)-7-methoxy-chromen-4-one |
3,5-dihydroxy-2-(4-hydroxy-3-methoxyphenyl)-7-methoxy-4h-chromen-4-one |
flavone, 3,4',5-trihydroxy-3',7-dimethoxy- |
276ck9gp9y , |
unii-276ck9gp9y |
rhamnacine |
NCI60_027977 |
nsc678106 |
3,4'-trihydroxy-7,3'-dimethoxyflavone |
rhamnazin |
nsc-678106 |
CHEBI:133721 |
552-54-5 |
3',7-dimethylquercetin |
FT-0667551 |
CHEMBL457148 , |
7,3'-di-o-methylquercetin |
3,4',5-trihydroxy-3',7-dimethoxyflavone |
LMPK12112641 |
bdbm50292355 |
3,5-dihydroxy-2-(4-hydroxy-3-methoxyphenyl)-7-methoxychromen-4-one |
SCHEMBL39443 |
quercetin 3',7-dimethyl ether |
quercetin 7,3'-dimethyl ether |
4h-1-benzopyran-4-one, 3,5-dihydroxy-2-(4-hydroxy-3-methoxyphenyl)-7-methoxy- |
7,3'-dimethylquercetin |
3,7-dimethoxy-3',4',5-trihydroxyflavone |
c.i. 75700 |
3,5-dihydroxy-2-(4-hydroxy-3-methoxyphenyl)-7-methoxy-4h-chromen-4-one # |
MYMGKIQXYXSRIJ-UHFFFAOYSA-N |
DTXSID00203695 |
rhamnazin, >=99% (hplc) |
Q3116746 |
rhamnazin with hplc |
3 inverted exclamation mark ,7-di-o-methyl quercetin |
CS-0143327 |
HY-N8342 |
E87182 |
AKOS040760673 |
Rhamnazin (RN) is a flavonol isolated from the calyxes and fruits of Physalis alkekengi L. It is known for its antioxidant and anti-inflammatory properties.
Excerpt | Reference | Relevance |
---|---|---|
"Rhamnazin (RN) is a flavonol isolated from the calyxes and fruits of Physalis alkekengi L. " | ( The alleviative effect of flavonol-type Nrf2 activator rhamnazin from Physalis alkekengi L. var. franchetii (Mast.) Makino on pulmonary disorders. Hu, HX; Lou, HX; Shen, T; Wang, T; Wang, XN; Wu, XY; Zhang, K; Zhao, BB; Zhao, Y, 2022) | 2.41 |
"Rhamnazin is a natural flavonoid and known for its antioxidant and anti-inflammatory properties." | ( ANTIOXIDANT AND ANTI-INFLAMMATORY EFFECTS OF RHAMNAZIN ON LIPOPOLYSACCHARIDE-INDUCED ACUTE LUNG INJURY AND INFLAMMATION IN RATS. Dai, X; Jiang, H; Li, X; Wu, G, 2017) | 1.44 |
Excerpt | Reference | Relevance |
---|---|---|
"The rhamnazin pretreated group also showed activation of Nrf2 pathway and attenuation of ROS such as H" | ( ANTIOXIDANT AND ANTI-INFLAMMATORY EFFECTS OF RHAMNAZIN ON LIPOPOLYSACCHARIDE-INDUCED ACUTE LUNG INJURY AND INFLAMMATION IN RATS. Dai, X; Jiang, H; Li, X; Wu, G, 2017) | 1.2 |
Role | Description |
---|---|
plant metabolite | Any eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms. |
antineoplastic agent | A substance that inhibits or prevents the proliferation of neoplasms. |
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Class | Description |
---|---|
dimethoxyflavone | Any methoxyflavone with two methoxy substituents. |
trihydroxyflavone | Any hydroxyflavone carrying three hydroxy groups at unspecified positions. |
aromatic ether | Any ether in which the oxygen is attached to at least one aryl substituent. |
phenols | Organic aromatic compounds having one or more hydroxy groups attached to a benzene or other arene ring. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Pathway | Proteins | Compounds |
---|---|---|
polymethylated quercetin biosynthesis | 2 | 10 |
polymethylated quercetin biosynthesis | 2 | 11 |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Aldo-keto reductase family 1 member B1 | Sus scrofa (pig) | IC50 (µMol) | 91.0000 | 0.0150 | 0.6135 | 2.5000 | AID354608 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID354609 | Inhibition of pig kidney aldehyde reductase by spectrophotometry | 1996 | Journal of natural products, Apr, Volume: 59, Issue:4 | Effect of Polygonum hydropiper sulfated flavonoids on lens aldose reductase and related enzymes. |
AID426928 | Antiviral activity against HSV1 infected in african green monkey Vero cells assessed as total inhibitory concentration after 3 days by plaque reduction assay | 2009 | Journal of natural products, Jun, Volume: 72, Issue:6 | 7-O-methylkaempferol and -quercetin glycosides from the whole plant of Nervilia fordii. |
AID426927 | Cytotoxicity against african green monkey Vero cells after 3 days by MTT assay | 2009 | Journal of natural products, Jun, Volume: 72, Issue:6 | 7-O-methylkaempferol and -quercetin glycosides from the whole plant of Nervilia fordii. |
AID354608 | Inhibition of pig lens aldose reductase by spectrophotometry | 1996 | Journal of natural products, Apr, Volume: 59, Issue:4 | Effect of Polygonum hydropiper sulfated flavonoids on lens aldose reductase and related enzymes. |
AID354610 | Inhibition of bovine liver NADH oxidase | 1996 | Journal of natural products, Apr, Volume: 59, Issue:4 | Effect of Polygonum hydropiper sulfated flavonoids on lens aldose reductase and related enzymes. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (10.00) | 18.2507 |
2000's | 1 (10.00) | 29.6817 |
2010's | 2 (20.00) | 24.3611 |
2020's | 6 (60.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (24.33) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 13 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |